Trending Now
  • Consumer Legal Funding: Beyond the Headlines, the Facts Tell a Different Story
  • An LFJ Conversation with Eric Schurke, CEO, North America, Moneypenny

The Secret to Success with Trade Secrets – 5 Factors That Litigation Funders Should Consider When Evaluating Trade Secrets Cases

The Secret to Success with Trade Secrets – 5 Factors That Litigation Funders Should Consider When Evaluating Trade Secrets Cases

The following article is a contribution from Ben Quarmby and Jonathan E. Barbee, Partner and Counsel at MoloLamken LLP, respectively.  Litigation funders have trade secrets on their minds.  Since the introduction of the Defend Trade Secrets Act (DTSA) in 2016, trade secrets litigation has been on the rise.  Over a thousand trade secrets cases were filed in federal court in both 2021 and 2022.  By all accounts, that trend is set to continue.  Big verdicts have followed, with some trade secrets verdicts now rivaling the biggest patent verdicts.  In the information age, a company’s most valuable intellectual property may not be its patents after all, but the wealth of non-patented, proprietary information surrounding its ideas—its trade secrets. Trade secrets cases can be more attractive to litigation funders than patent cases.  The funding of patent deals is regularly scuttled by patent expirations, validity concerns (especially Section 101 patent eligibility concerns), the threat of inter partes reviews (IPRs) at the United States Patent and Trademark Office, and the perceived focus of the Federal Circuit on reversing the largest patent verdicts that come before it.  Trade secrets side-step many of these issues.  They do not expire.  They are less likely to be sunk by an obscure prior art reference.  They are not subject to IPR proceedings.  And they are generally not subject to scrutiny by the Federal Circuit.  They also offer many of the same benefits to plaintiffs as patent cases: they too can be rooted in invention stories that will resonate with juries and lead to exemplary damages. They offer their own challenges, of course.  Unlike patent cases, there is no “innocent” misappropriation with trade secrets.  A defendant must often come into contact with the plaintiff’s trade secrets for a claim to arise.  Successful trade secret claims usually require a chain of events that put the trade secrets in the hands of the defendant.  Patent plaintiffs do not face those hurdles. Finding promising trade secrets cases requires identifying the types of companies that will regularly find themselves in situations that lead to trade secret misappropriation: joint ventures, startups seeking investment by larger industry players, acquisition targets, and companies operating in industries with high employee turnover and mobility.  And once those cases are found, performing due diligence on them requires a very specific type of focus. The following steps are critical:
  • Identify the Trade Secrets. Ensure at the outset that there are clean, concrete, and well-defined trade secrets to assert.  In some jurisdictions, plaintiffs must identify their trade secrets before proceeding with discovery—failure to do so with sufficient precision can stop the litigation dead in its tracks.  If plaintiffs can clearly identify the form of the trade secrets (e.g., scientific data, customer lists, product recipes, hard copy documents, etc.), the chain of custody for those trade secrets, and any changes made to the trade secrets over time, their case is far more likely to withstand the test of litigation.
  • Verify the Plaintiff’s Protective Measures. Defendants will generally argue that a plaintiff has not taken adequate steps to protect its trade secrets.  You need a clean and clear story to tell about the steps a plaintiff has taken to protect its intellectual property.  Tangible evidence of such steps—company policies, firewalls, passwords—is invaluable.  And there should be a narrow or controlled universe of third parties—if any—with whom the information has been shared.  Each additional third party with access to the information can increase the uncertainty surrounding the trade secrets and affect the value of the case.
  • Estimate the Value of Trade Secrets. Calculating damages in trade secrets cases can be trickier than in patent cases.  It is harder to find comparable licenses or valuations for similar types of trade secrets since trade secrets are just that—secret.  There are also fewer established damages methodologies in trade secrets cases.  While this allows for more flexibility and creativity in crafting a damages theory, it can also make trade secret damages susceptible to challenges.  The Georgia-Pacific factors used so often in patent cases can help determine reasonable royalty rates in trade secrets cases, but courts have yet to adopt those factors as the definitive standard for trade secrets.  In conducting due diligence, hire a damages expert to estimate the value of trade secrets before filing a case.
  • Assess the Value of Injunctive Relief. Trade secrets cases are often better candidates for injunctive relief than patent cases.  Determine the strength of a case’s injunctive relief prospects early on.  The likelihood of injunctive relief has to be factored into the economic value of a trade secrets case, since it will directly impact the likelihood of early settlement.
  • Determine the Narrative. Storytelling matters in every IP case.  But it perhaps matters in trade secrets cases even more so.  It is imperative to have reliable witnesses who can illustrate the plaintiff’s narrative in a compelling and clean way.  Test the potential witnesses before considering funding.  Let them tell their story—and challenge that story—under conditions that will most closely approximate those at trial.  Attractive cases should tell a persuasive story about how the trade secrets reflect plaintiffs’ know-how, experience, and competitive edge, and also expose the motives for defendants to steal those trade secrets.
These considerations are a starting point.  Due diligence should be tailored to the particular facts and nuances of each potential trade secrets case.  Careful consideration of these factors will help ensure that funders make the wisest investments, while avoiding common pitfalls in trade secrets litigation.

Commercial

View All

ARAG UK Posts £244M Income in First Results Including DAS, But Integration Costs Keep It in the Red

ARAG has reported total UK income of £244 million for the 2025 financial year, its first set of results to include the former DAS UK business, though the cost of absorbing that acquisition kept the legal expenses insurer at a pre-tax loss.

As reported by Legal Futures, ARAG Legal Expenses Insurance Company recorded income of £216.7 million, up more than 50% on the £141.4 million DAS reported a year earlier following the integration of the ARAG plc business. Growth was driven in particular by the strength of ARAG's before-the-event portfolio, with commercial products singled out.

ARAG LEI posted a pre-tax loss of £4.1 million, narrowed from a £5.5 million loss in 2024. The company attributed the shortfall mainly to the continuing cost of integrating the former DAS UK operations and consolidating the businesses under one roof at Trinity Quay in central Bristol. The UK consolidated businesses, which include ARAG plc and ARAG Law, contributed £8.9 million net of reinsurance to the international ARAG Group.

ARAG SE acquired DAS UK in 2024. The combined UK operation now insures more than 10 million families and roughly two million businesses against unforeseen legal costs, and recently launched its Insuring Justice social impact report at the House of Commons.

ARAG UK chief executive David Haynes said the business now contributes more than €250 million in income to the international group, "making the UK business ARAG's most significant operation outside Germany." He said the company was continuing its strong performance into 2026. In May, the international ARAG Group reported income of €3.2 billion, ahead of the target it had set for 2030.

Trucking Industry Tallies Four New State Funding Laws as Ohio’s Foreign-Investment Ban Takes Effect October 6

Four states have put new third-party litigation funding restrictions on the books this year, and the trucking industry that lobbied for several of them is already pressing for more.

As reported by Transport Topics, North Carolina went furthest. Governor Josh Stein signed the Prohibit Litigation Investments Act in June, making it illegal to provide litigation investments to a party or attorney in a civil action in the state. The ban took effect June 22 and applies to proceedings filed on or after that date, as well as to contracts entered into, renewed or amended afterward. Violations carry fines of up to $50,000 per offense, enforced by the attorney general.

Ohio's House Bill 105, signed by Governor Mike DeWine on July 7, takes effect October 6. It bars foreign governments, corporations and investors from participating in third-party litigation financing, prohibits funders from directing legal strategy or selecting counsel, and blocks plaintiffs and attorneys from sharing sealed or protected material with commercial funders. Funding agreements must disclose the amount advanced, the fees charged, how those fees accrue and the maximum a consumer could owe, and attorneys must provide agreements to the attorney general within 14 days of resolution.

Illinois House Bill 5487, signed August 7 and effective immediately, prohibits investors including private equity firms and hedge funds from interfering with the attorney-client relationship or controlling client records, and restricts fees tied to law firm revenue or profits. Mississippi's Transparency in Consumer Legal Funding Act took effect July 7, requiring funders to disclose to the attorney general the identity and country of incorporation of foreign entities with access to proprietary information.

Ohio Trucking Association president Tom Balzer called the legislation "a good step forward" and said further reforms are planned.

Novarex Closes £16M Second Round at a Stated 20% Return, With a Third Round Planned at 16.5%

Novarex Capital Partners has closed a second financing round of £16 million, more than tripling the size of its opening £5 million raise and bringing total capital generated across the programme to £21 million.

As reported by Pulse 2.0, the London-based platform completed the round on terms providing investors a stated return of 20%. A further round is already planned, structured around a stated return of 16.5%, though Novarex has not disclosed its timing or terms. The firm also declined to name the participants in the £16 million round or detail its contractual structure.

The capital supports the working capital requirements of an unnamed law firm regulated by the Solicitors Regulation Authority that prepares eligible legal claims. Novarex said the underlying firm operates within applicable SRA standards, maintains professional indemnity insurance, and handles client money and case processes inside the regulatory framework. The firm has a pipeline of contracted work and focuses on claims meeting established eligibility criteria.

Novarex describes itself as a specialist introduction platform covering private credit, litigation finance and structured capital, connecting sophisticated investors with private-market opportunities built around defined transaction parameters. It closed its initial £5 million round in August.

The structure is a familiar one in the UK consumer claims market, where law firms preparing high volumes of cases face significant upfront costs long before any recovery arrives, and where outside capital has increasingly filled the working capital gap. It is also the model drawing regulatory attention, with the SRA consulting on new rules governing solicitors' involvement in litigation funding arrangements following a series of claims firm failures.